Effect of Complementary Therapy with Purslane in Nonalcoholic Fatty Liver Disease

Effect of Complementary Therapy with Hydro-Ethanolic Extract of Aerial Parts of Purslane on Clinical and Paraclinical Findings in Patients with Nonalcoholic Fatty Liver Disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211116053073N1

Enrollment

Registered

2021-12-01

Start date

2021-12-24

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver- hepatic steatosis and fibrosis-hydro-ethanolic extract of aerial parts of Purslane. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: in addition to lifestyle interventions (diet therapy + physical activity), supplementation of hydro-ethanolic extract of aerial parts of Purslane with a dose of 700

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Detection of Hepatic Steatosis by Two-Dimensional Elastography Device Consent to Enter the Scheme Fatty Liver Patients with Grade F0 and F1

Exclusion criteria

Exclusion criteria: Pregnancy and Lactation Diseases such as: Diabetes, Autoimmune Disorders, Cancer, Liver Failure, Viral Hepatitis History, Liver Surgery and Renal Impairment (GFR <50) History of Food Allergy to Purslane and Herbal Supplements Taking Hepatoxic Drugs such as Amiodarone, Sodium Valproate or Methotrexate Body Mass Index more than 40 Consumption of Alcohol more than 30 grams per day for Men and also Consumption of more than 20 grams per day for Women History of Bariatric Surgery Fatty Liver Patients with F2, F3, F4 Grades Consumption of any Multivitamin Supplement and Antioxidant Compounds such as Vitamins C, E and Herbal Medicines during the Intervention Period

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis and fibrosis. Timepoint: before and at the end of the study. Method of measurement: Two-dimensional elastography device.	—

Secondary

Measure	Time frame
Evaluation of IPAQ physical activity questionnaire and three-day food recall. Timepoint: Before, in the middle and at the end of the study. Method of measurement: statistical methods.;Measurement of serum concentrations of lipid profiles including TC, HDL-C, LDL-C and TG. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of fasting blood glucose and insulin. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of hepatic profiles including ALT, ALP ,AST,GGT. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of inflammatory markers including ESR and Hs-CRP. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of anthropometric indices. Timepoint: Before, in the middle and at the end of the study. Method of measurement: Scales, meters,.;Measurement of body composition by BIA device. Timepoint: Before, in the middle and at the end of the study. Method of measurement: BIA.;Measurement of serum concentrations of oxidative stress indicators including malondialdehyde, glutathione. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.	—

Measure

Time frame

Evaluation of IPAQ physical activity questionnaire and three-day food recall. Timepoint: Before, in the middle and at the end of the study. Method of measurement: statistical methods.;Measurement of serum concentrations of lipid profiles including TC, HDL-C, LDL-C and TG. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of fasting blood glucose and insulin. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of hepatic profiles including ALT, ALP ,AST,GGT. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of serum concentrations of inflammatory markers including ESR and Hs-CRP. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.;Measurement of anthropometric indices. Timepoint: Before, in the middle and at the end of the study. Method of measurement: Scales, meters,.;Measurement of body composition by BIA device. Timepoint: Before, in the middle and at the end of the study. Method of measurement: BIA.;Measurement of serum concentrations of oxidative stress indicators including malondialdehyde, glutathione. Timepoint: Before and at the end of the study. Method of measurement: Laboratory methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Milkarizi

Mashhad University of Medical Sciences

Milkarizin991@mums.ac.ir+98 51 3800 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026